1. Bronkhial'naya astma. Global'naya strategiya. Natsional'nyi Institut Serdtse, Legkie i Krov'. Izdanie № 95-3659. Yanvar' 1995. Russkaya versiya pod redaktsiei akad. A.G.Chuchalina. Pul'monologiya 1996; Pril.
2. The British guidelines on asthma management. Thorax 1998; 52: suppl. 1.
3. Chuchalin L.G., Mednikov B.L., Belevskii A.C. i dr. Bronkhial'naya astma. Rukovodstvo dlya vrachei Rossii. (Formulyarnaya sistema). Pul'monologiya 1999; Pril.
4. Khronicheskie obstruktivnye bolezni legkikh. Federal'naya programma. M.; 1999.
5. Huchon G. Metered dose inhalers: past and present: advantages and limitations. Eur. Respir. Rev. 1997; 41: 26-28.
6. Tsoi L.N. Preimushchestva i nedostatki prisposoblenii dlya individual'noi ingalyatsionnoi terapii. Pul'monologiya 1997; 3: 71-74.
7. Ogorodova JI.M. Sistemy ingalyatsionnoi dostavki preparatov v dykhatel'nye puti. Tam zhe 1999; 1: 84-87.
8. Matthys I. CFCs and their effect on the ozone layer: the Montreal protocol and consequences for physicians. Eur. Respir. Rev. 1997; 7: 29-31.
9. Boulet L.P. The ozone layer and metered dose inhalers. Can. Respir. J. 1998; 5: 176-179.
10. Chronic Obstructive Pulmonary Disease (COPD) is a major health and socioeconomic burden; one of the top five causes of disability and death in industrial societies. Personal communication: http://www.boehringer-ingelheim.com.
11. Ensuring patient care. The role of the HFC MDI. 2nd ed. Washington, D. C.: IPAC; 1999.
12. Goldberg J., Schmidt P., Freund E. et al. 12-week safety and efficacy study of fenoterol hydrobromide MDI formulated with HFA 134a or CFC in patients with asthma. Personal communication: http://www.boehringer-ingelheim.com.
13. Vermeulen J., Boshof L., Lowe L.S. et at. Fenoterol delivered via HFA metered dose inhaler (MDI) is as safe and effective as CFC delivery in the long-term treatment of children with asthma. Eur. Respir. J. 1999; 14 (suppl. 30): 180S, abstr. P1267.
14. Leclerk V., Thebablt J.J., Iacono P. et al. Dose-response to fenoterol MDI with non-CFC propellant HFA 134a is equivalent to CFC-MDI in patients with asthma. Personal communication: http://www.boehringer-ingelheim.com.
15. Huchon G., Hofbaner P., Cannizaro G. et at. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO. Eur. Respir. J. 2000; 15: 663-669.
16. "Anwendungsbeobachtug". Personal communication: http://www.boehringer-ingelheim.com.
17. Bateman E.D., Joubert L.R., Le Roux A.M. et al. Therapeutic equivalence of MDI formulation study in patients with asthma. Eur. Respir. J. 1997; 10 (suppl. 25): 240S, abstr. P1542.
18. Joubert J.R., Bateman E.D., Le Roux A.M. et al. Therapeutic equivalence of MDI formulations of fenoterol with HFA or CFC propellants: a dose confirmation study in patients with asthma. Personal communication: http://www.boehringer-ingelheim.com.
19. June D. Achieving the change: challenges and successes in the formulation of CFC-free MDIs. Eur. Respir. Rev. 1997; 7 (41): 32-34.
20. Zoidis J.D. Your metered-dose inhaler will be changing. RT Magazine 1998; 11: 27-35.
21. Molina M.J., Rowland F.S. Stratospheric sink for chlorofluoromethanes, chlorine atom-catalyzed destruction of ozone. Nature 1974; 249: 810-817.
22. Stolarski R.S., Cicerone R.J. Stratospheric chlorine: a possible sink for ozone. Can. J. Chem. 1974; 52: 1610-1624.
23. Montreal protocol on substances that deplete the ozone layer (Sept. 16, 1987. 26: ILM 1541). Montreal; 1987.